SPO OVER-ALLOTMENT OPTION PARTIALLY EXERCISED
(Thomson Reuters ONE) -
GHENT, Belgium - 13 April 2010 - Ablynx [Euronext Brussels: ABLX], the
biopharmaceutical company focused on the discovery and development of
Nanobodies(®), announces that KBC Securities, acting on behalf of the bank
underwriting syndicate of its Secondary Public Offering (the "SPO" or
"Offering") completed in March 2010, has partially exercised the Over-allotment
Option on 13 April 2010, in accordance with provisions contained in the SPO
prospectus.
At the SPO, 400,000 over-allotment shares had been allotted. Such shares were
lent by the Lending Shareholders (ACP IV, L.P., KBC Private Equity NV and VIB
VZW). The partial exercise of the Over-allotment Option will result in a total
of 219,107 shares being sold by the Lending Shareholders at the SPO offer price,
i.e. ?7.5 per share. On 31 March, 6 and 8 April 2010, stabilisation transactions
were carried out for a total of 180,893 shares all at the offer price i.e. ?7.5
per share.
As a result, a total of 6,885,774 shares of Ablynx NV will have been placed on
the market in the Offering, equal to approximately ?51.64 million (at the offer
price).
Transfer and payment of shares related to the partial exercise of the
Over-allotment Option will take place on 16 April 2010.
KBC Securities NV and UBS Investment Bank acted as Joint Global Coordinators and
Joint Bookrunners, while Piper Jaffray Ltd. acted as Co-Manager to the Offering.
-ends-
About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused
on the discovery and development of Nanobodies, a novel class of therapeutic
proteins based on single-domain antibody fragments, for a range of serious and
life-threatening human diseases. The Company currently has over 230 employees.
Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November
2007 and raised ?50 million through an SPO in March 2010.
For more information, please contact Ablynx:
Dr. Edwin MosesChairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e:edwin.moses(at)ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e:eva-lotta.allan(at)ablynx.com
Wim Ottevaere
Chief Financial Officer
t: +32 (0)9 262 00 08
e:wim.ottevaere(at)ablynx.com
[HUG#1403325]
Complete version of the press release : http://hugin.info/137912/R/1403325/357618.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Mirasol Confirms High-Grade Silver Results through Infill Channels at the Julia Vein, ArgentinaDatum: 13.04.2010 - 15:17 Uhr
Sprache: Deutsch
News-ID 1012830
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Ghent
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"SPO OVER-ALLOTMENT OPTION PARTIALLY EXERCISED
"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
